Private Health Insurance (Health Benefits Fund Policy) Rules 2025

The Rules rest on a small set of tightly defined concepts. The instrument depends on the Act’s existing definitions for a number of terms and adds precise specifications where the Act permits or requires matters to be prescribed.

Act and cross‑reference: The instrument is made under the Private Health Insurance Act 2007 (rule 3). Rule 4 confirms that many key expressions are defined in the Act (for example, general treatment, health benefits fund, hospital treatment, medicare benefit, policy holder, private health insurer), and the instrument uses those Act definitions where relevant.

Specified health‑related businesses (s 131‑15(1)(d) context): Part 2 lists two specified businesses for the purposes of paragraph 131‑15(1)(d) of the Act.

• Overseas treatment (rule 6). This is insurance of liability for providing treatment to a person outside Australia to manage a disease, injury or condition, but only where cumulated conditions are met. The subrule (2) sets four requirements: the condition must be chronic and permanent (6(2)(1)); liability must be confined to treatment that would be required routinely, whether or not the person had remained in Australia (6(2)(2)); the liability for any particular treatment cannot exceed the liability that would be incurred if the treatment were provided in Australia (6(2)(3)); and liability cannot extend to any treatment administered more than 60 days after the person last departed Australia (6(2)(4)). The specification is therefore narrow: it covers recurring, routine treatment for chronic, permanent conditions for a limited overseas period and caps liability to an Australian equivalent.

• Agency business (rule 7). The instrument specifies as business of offering goods, services or benefits under an agency arrangement. It defines “agency arrangement” as a written arrangement where (a) the agent is permitted to act on behalf of the principal to create legal relations between the principal and a third person in transactions to provide goods, services or benefits; (b) the principal assumes liability for the transaction to the third person, including provision of the goods, services or benefits; and (c) the agent assumes no liability in respect of the transaction, other than to perform its obligations under the arrangement (7(2)(a)-(c)). The instrument provides an illustrative example (an insurer offering travel insurance policies where an overseas principal assumes the insurable risks and the insurer acts as agent and takes on no such liabilities except contractual obligations).

Risk equalisation jurisdictions (s 131‑20(1) context): Rule 8 lists the areas that are risk equalisation jurisdictions for subsection 131‑20(1) of the Act, enumerating seven items that map to States and Territories or grouped collections that include external Territories (8(1)(items 1-7)).

Operational constraint through health benefits funds (s 131‑25 context): Rule 9 applies where a private health insurer has a health benefits fund relevant to both its health insurance business and some or all health‑related businesses (9(1)). For the purposes of section 131‑25 of the Act, the insurer must not take actions or have regard to matters that would result in “improper discrimination” regarding people insured or wishing to be insured under overseas student health insurance contracts or specified temporary visa holder health insurance contracts (9(3)). The instrument then defines improper discrimination exhaustively across seven categories, including chronic disease status, protected characteristics (gender, race, sexual orientation, religious belief), age, residence, other characteristics likely to increase need for hospital or general treatment, frequency of need for treatment, and the amount or extent of benefits a person becomes entitled to during a period, subject to an exception where a written agreement between the insurer and the Commonwealth permits otherwise (9(4)).

Cross‑references to other Rules: The instrument expressly adopts the same meanings as the Private Health Insurance (Health Insurance Business) Rules 2018 for the terms overseas student, overseas student health insurance contract, specified temporary visa holder and specified temporary visa holder health insurance contract (rule 9 final paragraph), so compliance requires reading that instrument alongside these Rules.

Commencement mechanics: The commencement table (rule 2) states that the whole instrument commences the day after registration; it includes the usual statutory note that the table relates only to the instrument as originally made.

Repeal: Schedule 1 repeals the whole Private Health Insurance (Health Benefits Fund Policy) Rules 2015.

These components together define the instrument’s substantive scope: narrow overseas treatment coverage, formalised agency arrangements as specified business, a listed set of risk equalisation jurisdictions, and a specified non‑discrimination duty for insurers operating particular programs through health benefits funds.

The Rules affect a defined set of parties directly and others indirectly through operational impacts under the Act.

Private health insurers: The primary regulated parties are private health insurers. The instrument applies directly to private health insurers exercising health insurance business and health‑related business activities, in particular those insurers that operate a health benefits fund “in respect of” their health insurance business and some or all of their health‑related businesses (rule 9(1)). Where those conditions are met, the insurer must comply with the non‑discrimination constraints in rule 9.

Health benefits funds: Where an insurer has a health benefits fund in respect of its health insurance business and some or all health‑related businesses, that fund is the vehicle through which the rule 9 obligations are triggered (9(1)). The instrument therefore targets the governance and conduct of health‑related businesses conducted through a fund.

Overseas students and specified temporary visa holders: Individuals who are, or wish to be, insured under an overseas student health insurance contract or a specified temporary visa holder health insurance contract are beneficiaries of the non‑discrimination rule 9(3). The instrument cross‑refers to the Private Health Insurance (Health Insurance Business) Rules 2018 for the definitions of overseas student and specified temporary visa holder; thus the population covered depends in part on those definitions.

Agents and principals in agency arrangements: The specification of agency business (rule 7) regulates the treatment of offers made under written agency arrangements by private health insurers. The rule defines the relationship elements that must exist for the business to be specified , the agent acts to create legal relations for the principal, the principal assumes liability for the transaction, and the agent assumes no liability except to perform its contractual obligations (7(2)(a)-(c)). Therefore private health insurers acting as agents, principals who contract with insurers, and third‑party providers who buy the offer interact with these requirements.

Providers of overseas treatment cover (insurers, overseas travel insurance companies): Rule 6 specifies certain overseas treatment arrangements as health‑related business, but only under narrow conditions (chronic and permanent conditions; routine treatment; Australian cost cap; 60‑day limit). Insurers offering such coverage to persons outside Australia will need to structure product design and liability exposure accordingly.

Government agencies administering the Act and the Department of Health, Disability and Ageing: The Rules are made under the Act (rule 3) and will be used by the Department and the regulator to determine how the specified provisions of the Act apply in practice. The instrument also references written agreements between private health insurers and the Commonwealth (rule 9(4) exception), so Commonwealth contracting parties are affected.

Jurisdictions and risk equalisation administrators: The list of risk equalisation jurisdictions (rule 8(1)) affects how risk equalisation provisions in the Act are applied across States, Territories and external Territories. Entities calculating or administering risk equalisation adjustments will use this list.

Indirectly affected parties: Insured persons more broadly may be affected where insurers’ product design and underwriting change because of these specifications. For example, insurers may alter product inclusions for overseas students if the non‑discrimination constraint or the overseas treatment specification changes their liability management. Insurers offering agency arrangements with overseas principals will be affected by the requirement that the principal assume liability, which may shift commercial negotiations.

Scope limits: Note that rule 9 applies only where the insurer “has a health benefits fund in respect of its health insurance business and some or all of its health‑related businesses” (9(1)). Insurers that do not operate a health benefits fund in that manner are outside the immediate scope of rule 9, though they remain subject to other parts of the Act and the instrument where relevant (for example, an insurer conducting the specified agency business would fall within rule 7).

Timing: The Rules commence the day after registration (rule 2), and they repeal the 2015 Rules in full (Schedule 1), so stakeholders should anticipate any administrative and contractual adjustments from that date.

This instrument creates a set of specific duties (largely prohibitions) and confirms certain rights or structuring options that private health insurers may rely on. All duties and rights flow from the Rules’ specification of business and interaction with the Act.

Duties , non‑discrimination for certain products offered through health benefits funds: The clearest substantive duty is in rule 9. Where a private health insurer has a health benefits fund in respect of its health insurance business and some or all of its health‑related businesses (9(1)), the insurer must not take any action or omit to take any action, nor have regard to or fail to have regard to any matter in making a decision, that would result in the insurer improperly discriminating between people who are, or wish to be, insured under an overseas student health insurance contract or a specified temporary visa holder health insurance contract of the insurer (9(3)). This is a preventative duty framed as a prohibition on conduct and decision‑making that would produce the specified discriminatory outcomes.

Definition of improper discrimination: The instrument elaborates what constitutes “improper discrimination” in rule 9(4) across seven categories: suffering from chronic disease or other medical condition or a particular kind of disease (9(4)(a)); gender, race, sexual orientation or religious belief (9(4)(b)); age (9(4)(c)); place of residence (9(4)(d)); any other characteristic likely to increase need for hospital or general treatment (9(4)(e)); frequency of need for hospital or general treatment (9(4)(f)); and the amount or extent of benefits a person becomes entitled to during a period under the relevant contract (9(4)(g)). The last category is subject to an exception “except to the extent allowed by the written agreement, made between the private health insurer and the Commonwealth, referred to in the definition of overseas student health insurance contract and specified temporary visa holder health insurance contract in the Private Health Insurance (Health Insurance Business) Rules 2018” (9(4)(g)). The duty therefore has both substantive scope and a contractual exception where the Commonwealth agreement permits differential treatment.

Duties on specification of health‑related business: Rules 6 and 7 specify the types of business captured by paragraph 131‑15(1)(d) of the Act. When insurers undertake the businesses specified, those activities are treated as health‑related business for the Act’s purposes, and the insurer will be subject to whatever statutory requirements or constraints the Act attaches to health‑related business. For overseas treatment, rule 6(2) imposes substance limits (chronic/permanent condition; routine treatment only; Australian cost cap; 60‑day post‑departure limit), which constrain insurers’ liability when offering such cover.

Rights, structuring options and clarifications:

• Agency arrangement structure: Rule 7(2) sets out the three elements of a permitted agency arrangement. An insurer may therefore structure activity as agent or principal, but if the activity is to be treated as the specified agency business for the Act, the written arrangement must show the agent acting to create legal relations for the principal, the principal assuming liability for the transaction (including benefits provision), and the agent assuming no liability for the transaction except to perform obligations under the arrangement (7(2)(a)-(c)). The instrument explicitly notes an example where a private health insurer offers travel insurance policies under an arrangement with an overseas travel insurance company as principal (rule 7, note).

• Liability cap for overseas treatment: For covered overseas treatment, rule 6(2)(3) expressly restricts liability to no more than what would be incurred if treatment were provided in Australia. That is a contractible ceiling the insurer can rely on to limit exposure.

• Time limitation: Rule 6(2)(4) caps liability for overseas treatment to services provided within 60 days after departure. An insurer may therefore exclude long‑term overseas care past that date for chronic conditions, subject to the specified conditions.

Cross‑instrument dependencies: The instrument draws definitions and exceptions from the Private Health Insurance (Health Insurance Business) Rules 2018 for terms such as overseas student and specified temporary visa holder. The right to treat benefit variances differently for those groups is therefore partially contingent upon what is allowed in the written agreement between insurer and Commonwealth under those 2018 Rules (rule 9(4)(g)).

Delegated authority: The Rules are made under the Act and by delegative instrument (the Rules themselves are made by a delegate , the instrument is headed by the delegate’s signature). Rights and duties in the Rules therefore operate within the overarching statutory framework of the Act (rule 3).

Operational consequence: If an insurer’s activity meets the specifications in rules 6 or 7, those activities will be treated as health‑related business for the specified Act subsections. If an insurer operates a health benefits fund as described in rule 9(1), it acquires the non‑discrimination duty in 9(3) and the scope defined in 9(4). The instrument locates duties as proscriptive obligations on actions, omissions, and the matters considered in decision‑making.

The Rules themselves do not set out enforcement mechanisms, administrative sanctions or monetary penalties. They are made under the Private Health Insurance Act 2007 (rule 3) and, where they specify matters “for the purposes of” particular sections of the Act (for example, paragraph 131‑15(1)(d), subsection 131‑20(1), and section 131‑25), the Act’s enforcement regime and any sanctions that it provides will govern compliance and remedies. The instrument relies on the Act to give the specifications legal traction.

Practical legal effect: Because the Rules operate by specifying what counts as health‑related business or by prescribing requirements for purposes of sections of the Act, failure to comply with a duty in the Rules (for example, improperly discriminating in the circumstances described in rule 9) will expose an insurer to whatever regulatory consequences the Act attaches to contraventions of the relevant statutory provisions. The instrument itself references the Act’s subsections , paragraph 131‑15(1)(d) (rules 6 and 7), subsection 131‑20(1) (rule 8), and section 131‑25 (rule 9) , and therefore enforcement and penalties must be determined by reference to those Act provisions and any general enforcement powers, administrative penalties, offences or civil remedies the Act sets out.

No independent penalty clauses: The Rules do not create new criminal offences, fines or civil penalties within their text. Schedule 1 simply repeals the previous instrument; it does not add enforcement mechanisms. For practical compliance and risk assessment, regulated entities will need to consult the Act and the regulator’s published enforcement policies to identify specific sanctioning mechanisms and processes.

Administrative oversight and interpretive role: The instrument will also be used administratively by the Department and by the regulator to interpret how the Act’s provisions apply. The Rules’ detailed specifications (for example, the four‑point test for overseas treatment at rule 6(2), the three‑part agency arrangement in rule 7(2), and the list of improper discrimination items in rule 9(4)) create compliance benchmarks the regulator can apply when assessing conduct. Where ambiguity arises about whether particular behaviour breaches the Act through contravention of these specified matters, enforcement action will follow the Act’s procedural and substantive rules.

Contractual and commercial remedies: The instrument contemplates written agreements between insurers and the Commonwealth as relevant to exceptions in rule 9(4)(g). Where a written Commonwealth agreement permits differences in benefit entitlements, that contractual arrangement will affect whether particular conduct is “improper discrimination” under the Rules. Enforcement of contractual obligations or disputes about the existence or effect of Commonwealth agreements will be resolved by usual contractual or administrative law means, subject again to the Act’s interface.

Recommendation within the instrument’s scope: For precise sanctions, civil remedies, administrative penalty regimes, or criminal offences that may apply following a breach of the specified duties, readers must consult the Private Health Insurance Act 2007 because the Rules do not create or list penalties; they operate by specification and reference (rule 3; see rules 6-9 for the specifications).

This instrument is not a stand‑alone regulatory regime; it operates as a rules instrument under the Private Health Insurance Act 2007 and cross‑references other rule instruments. Its interaction with other laws is therefore purely by reference and specification rather than by creating independent legal norms beyond the Act’s framework.

Primary statutory framework: The Rules are made under the Private Health Insurance Act 2007 (rule 3). Each specification in the instrument is tied to a subsection or paragraph of the Act: rule 6 and rule 7 are made for the purposes of paragraph 131‑15(1)(d) of the Act; rule 8 is for subsection 131‑20(1); rule 9 is for section 131‑25. Therefore the operation of each rule must be read together with those Act provisions. The instrument does not alter the Act; it supplies particulars that the Act permits to be prescribed.

Interaction with the Private Health Insurance (Health Insurance Business) Rules 2018: Rule 9 explicitly imports terminology from the Private Health Insurance (Health Insurance Business) Rules 2018 by stating that certain terms have the same meaning as in that instrument: overseas student; overseas student health insurance contract; specified temporary visa holder; specified temporary visa holder health insurance contract (rule 9, final paragraph). Rule 9(4)(g) also refers to “the written agreement, made between the private health insurer and the Commonwealth, referred to in the definition of overseas student health insurance contract and specified temporary visa holder health insurance contract in the Private Health Insurance (Health Insurance Business) Rules 2018.” That means the extent to which benefit‑based distinctions are permitted in rule 9(4)(g) depends directly on contractual arrangements under the 2018 Rules. Compliance thus requires reading the 2025 Rules and the 2018 Rules together.

Repeal of the 2015 Rules: Schedule 1 repeals the Private Health Insurance (Health Benefits Fund Policy) Rules 2015 in full. Any legal positions or administrative practices that depended on the 2015 Rules must be reassessed against the 2025 Rules. The repeal takes effect on commencement, which is the day after registration (rule 2), so the 2015 Rules cease to have force from that date.

No express interaction with other federal statutes in the instrument: The Rules reference “medicare benefit” as a defined term in the Act (rule 4 notes the Act contains the definition), but they do not otherwise create positive obligations that interact directly with Medicare billing, social security law, or migration law. If other Commonwealth laws affect overseas students or specified temporary visa holders (for example, migration law conditions), the instrument does not purport to modify those laws; it addresses health‑related business classification and non‑discrimination in the context of the Act’s private health insurance regulation.

Contractual relationships with the Commonwealth: Rule 9(4)(g) makes explicit that written agreements between private health insurers and the Commonwealth (of the type referenced in the 2018 Rules) may allow differential benefit entitlements. Such agreements therefore operate in tandem with these Rules to determine the permissible scope of insurer actions in relation to overseas students and specified temporary visa holders. Contract law and administrative contracting principles will therefore intersect with the interpretation and application of the non‑discrimination constraint.

Territorial application and risk equalisation: Rule 8 lists areas for the purposes of subsection 131‑20(1) of the Act. That listing affects how the Act’s risk equalisation provisions apply across States, Territories and external Territories (for example grouped areas such as the Australian Capital Territory, Norfolk Island and New South Wales). The instrument does not amend other statutes of those States or Territories; it merely identifies areas relevant for the Commonwealth’s risk equalisation calculations under the Act.

Regulatory interpretation and administrative law: Because the Rules supply detailed specifications for the purposes of the Act, administrative decision‑makers and courts (if disputes arise) will interpret the Act together with these Rules. For disputes invoking the Rules’ meaning or their application to conduct, judicial and tribunal review will proceed under general administrative law principles, applied to the Act and the instrument together.

The instrument contains the minimal internal amendment history necessary to deploy it in place of the prior instrument; there are no in‑text amendments, saves or transitional clauses aside from the repeal of the earlier Rules. The key historical facts are:

• Date and maker: The Rules are dated 30 July 2025 and are made by Paul McBride, delegate of the Minister for Health and Ageing, Assistant Secretary, Private Health Strategy Branch (instrument header). The signature block is included in the instrument.

• Commencement: The commencement table in rule 2 says the whole of this instrument commences the day after the instrument is registered. The instrument states the table relates only to the provisions as originally made and will not be amended to deal with later amendments. There are no staged commencements or transitional provisions.

• Repeal of 2015 instrument: Schedule 1 expressly repeals the whole of the Private Health Insurance (Health Benefits Fund Policy) Rules 2015 (Schedule 1, item 1). That is a full repeal; the 2015 Rules are not saved or grandfathered in any part by this instrument. There are no transitional rules in this instrument that preserve particular arrangements entered into under the 2015 Rules.

• No textual amendments listed: The instrument’s Schedules section (rule 5) provides the usual machinery: each instrument specified in a Schedule is amended or repealed as set out, and any other item in a Schedule has effect according to its terms. In this instrument, Schedule 1 contains only the single repeal entry. There are no other amendments or repeal‑plus‑save clauses.

• No subsequent amendments recorded in this text: The instrument contains no amendment schedule or history of prior iterations. It is therefore presented as a replacement instrument that takes effect from its commencement date and supersedes the 2015 Rules.

• Interpretation notes: Rule 2 contains the standard note that the table is part of the instrument only as to commencement and that notes or information in column 3 are not part of the instrument. This preserves standard legislative drafting practice and confirms there is no separate amendment history recorded within the instrument text beyond the full repeal.

For practitioners and compliance officers, the concrete takeaway is that, from the instrument’s commencement date (the day after registration), the 2015 Rules no longer apply and must be replaced in operational practice by the 2025 Rules. There is no transitional carve‑out in the instrument itself; any transitional treatment would need to be supplied by other administrative measures or agreements.

The text of the Rules contains no reference to litigation, court decisions, tribunal determinations or precedent. It does not cite any cases or judicial pronouncements. The instrument is a delegated rules instrument that specifies matters for the purposes of particular provisions of the Private Health Insurance Act 2007; it was made administratively and contains no litigation record.

Because the Rules are newly made and replace the 2015 Rules, there is, within the instrument, no litigation history to report. Any litigation that may later arise from the application, interpretation or enforcement of these Rules would be recorded outside the instrument in court or tribunal files and would need to be traced using external legal databases and court registries. Similarly, administrative decisions applying these Rules under the Act might give rise to merits review or judicial review, but there is no material in the instrument itself indicating prior litigation or contested interpretations.

If a practitioner requires information about existing or potential litigation that engages the Act provisions the instrument references (for example, disputes about paragraph 131‑15(1)(d), subsection 131‑20(1) or section 131‑25), they must consult case law or adjudicative records external to the Rules. The instrument’s silence on litigation does not imply absence of disputes; it simply contains no record of them.

This instrument contains several detail‑level features and cross‑dependencies that create practical traps if not read closely. Below are concrete items to look out for, each tied to the relevant rule reference.

Narrow scope for overseas treatment (rule 6): Rule 6(2) defines overseas treatment narrowly. Three elements are often conflated in practice but each must be satisfied:

• The disease, injury or condition must be chronic and permanent (6(2)(1)). Acute or temporary conditions are excluded from this specification.

• The liability must be confined to treatment “required routinely, whether or not the person had remained in Australia” (6(2)(2)). This phrase limits cover to routine management of chronic conditions, not episodic or exceptional interventions that might arise overseas.

• The insurer’s liability for any particular treatment cannot exceed what would be incurred if the treatment were provided in Australia (6(2)(3)). This is a hard cap: insurers must track and measure the Australian equivalent cost for specific treatments to ensure overseas payments do not exceed it.

• The liability does not extend to any treatment administered more than 60 days after the person last departed Australia (6(2)(4)). That 60‑day clock is absolute in the specification; cover beyond 60 days post‑departure falls outside the specified business.

Taken together, these constraints make it easy to misclassify overseas cover as “health‑related business” where one of the elements is not satisfied. For example, if a treatment is non‑routine or if the person’s condition is not chronic and permanent, the specification does not apply.

Agency arrangements , formal written requirements (rule 7): Rule 7(2) prescribes three elements of an “agency arrangement” and the arrangement must be written. Common practice risks here include:

• Failing to have a written arrangement that clearly records that the agent is permitted to act to create legal relations for the principal (7(2)(a)). Verbal or informal agency roles will not squarely fit the specified form.

• Allowing the agent to assume liability in the agreement, contrary to 7(2)(c). If the agent assumes liability beyond performance obligations under the written arrangement, the arrangement will not meet the instrument’s definition and so the business will not be specified as agency business.

• Assuming the insurer automatically avoids liability simply by calling a contract an “agency arrangement”. The specified tripartite features must all be present in the written document and in practice.

Cross‑instrument dependency for overseas student and specified visa holder definitions (rule 9): Rule 9 imports definitions from the Private Health Insurance (Health Insurance Business) Rules 2018. The exception in rule 9(4)(g) is particularly significant: the amount or extent of benefits to which a person is entitled may not be used as a discriminatory factor except to the extent allowed by a written agreement between the insurer and the Commonwealth as referred to in the 2018 Rules. Practitioners must therefore check the relevant Commonwealth agreements under the 2018 Rules to determine permissible variations. It is a two‑step analysis: (1) consult the 2025 Rules to see the non‑discrimination constraint; (2) consult the 2018 Rules and any written Commonwealth agreement to see whether and where exceptions are permitted.

Application only through a health benefits fund (rule 9(1)): Rule 9 applies only if “a private health insurer has a health benefits fund in respect of its health insurance business and some or all of its health‑related businesses.” If an insurer does not operate a health benefits fund in that manner, rule 9’s non‑discrimination duty may not be triggered. That conditionality can lead to compliance risk where insurers assume rule 9 applies across products without first confirming the fund structure.

Multiplicity of decision‑making dimensions (rule 9(3) and (4)): The prohibition in rule 9 covers acts and omissions and the matters considered (or not considered) in decision‑making. That is a broad framing. Compliance programmes must therefore cover underwriting criteria, administrative practices, automated decision logic, and even informal staff conduct. Failure to document reasons or to show what matters were considered may expose an insurer to regulatory scrutiny.

Territorial grouping for risk equalisation (rule 8): The instrument groups some jurisdictions together (for example, ACT, Norfolk Island and New South Wales; Western Australia with Christmas Island and Cocos (Keeling) Islands). Administrators and actuaries must map these groupings to their data aggregation and risk equalisation calculations; mismapping could distort statutory reporting.

Repeal without transitional provisions (Schedule 1): Schedule 1 repeals the 2015 Rules in full without providing transitional measures in this instrument. Entities relying on the 2015 Rules must implement changes immediately upon commencement or find administrative arrangements to bridge the repeal; absence of transitional provisions means contracts and operational processes should be reviewed sooner rather than later.

No penalties in the instrument (rule 3; general): Because penalties and enforcement mechanisms are not set out here but reside in the Act, some entities may underestimate regulatory risk if they rely solely on the Rules text. Practical compliance requires cross‑consultation with the Act.

Documentation and audit trail: Given the instrument’s emphasis on what insurers must not consider in decision‑making (rule 9(3)), insurers should keep contemporaneous records showing what factors were considered in each decision relating to overseas students and specified temporary visa holders. Failure to keep such records may make it harder to demonstrate compliance.

Practical example traps: For overseas treatment, compare the coverage offered to a departing person against the Australian cost of the same treatment and the date of last departure. Small errors in how “last departed from Australia” is recorded, or in mapping overseas services to Australian equivalents, will affect whether cover complies with rule 6(2)(3) and (4).

In summary, the principal “gotchas” are conditionality (application only through a fund), narrow technical tests (overseas treatment), strict written requirements (agency arrangements), cross‑instrument exceptions (Commonwealth written agreements under the 2018 Rules), and the need for robust documentation and governance to show that prohibited decision factors were not used.

Compliance requires deliberate operational, contractual and governance steps keyed to the instrument’s precise specifications. Below are concrete actions insurers and advisers should take, mapped to the relevant rules.

1. Confirm whether rule 9 applies (rule 9(1))

• Review corporate structure and product lines to determine whether the insurer “has a health benefits fund in respect of its health insurance business and some or all of its health‑related businesses.” If yes, rule 9 applies and the non‑discrimination duties follow. Document the fund relationship and the business lines included in the fund.

2. Review and amend underwriting and decision‑making frameworks (rule 9(3)-(4))

• For products marketed as overseas student health insurance or specified temporary visa holder health insurance, audit existing underwriting questions, exclusions, pricing algorithms and decision matrices to ensure none of the “improper discrimination” categories in rule 9(4) are used as prohibited decision criteria, unless expressly permitted by a written Commonwealth agreement under the 2018 Rules (9(4)(g)). This covers chronic disease status, gender, race, sexual orientation, religion, age, place of residence, other characteristics likely to increase treatment need, frequency of treatment need, and the amount or extent of benefits.
• Update policy wording, underwriting manuals, and automated decision logic to remove prohibited factors. For factors that potentially overlap permitted exceptions, obtain legal advice and retain the relevant written agreement in the contract file.

3. Contractual check for Commonwealth agreements (rule 9(4)(g))

• Identify whether written agreements exist between the insurer and the Commonwealth referenced in the Private Health Insurance (Health Insurance Business) Rules 2018. Where such agreements permit differential benefit entitlements, obtain copies, ensure interpretations are documented, and align internal systems to the contractual permissions.

4. Update agency arrangements and related documentation (rule 7(1)-(2))

• Ensure any “agency arrangement” that the insurer relies upon is in writing and contains the three elements required by rule 7(2): agent permitted to act to create legal relations for the principal (7(2)(a)), principal assumes liability for transactions and benefits (7(2)(b)), agent assumes no liability for the transaction other than performance of obligations under the arrangement (7(2)(c)).
• Where the insurer intends to offer goods, services or benefits by way of agency, ensure the principal assumes explicit liability in the written agreement. If the insurer will act as a principal, document the difference in liability exposure.
• Retain the written agency agreements and ensure operational teams maintain a ledger of active agencies and their liability allocations.

5. Product design for overseas treatment (rule 6(2))

• If offering cover that could be classified as the specified overseas treatment business, design the product to satisfy all four conditions in rule 6(2): (a) limit cover to chronic and permanent conditions only; (b) ensure cover is confined to routine treatment that would have been required had the person remained in Australia; (c) cap insurer liability for each treatment at the Australian equivalent cost; and (d) ensure no liability extends to treatment administered more than 60 days after last departure from Australia.
• Implement systems to map overseas treatments to Australian equivalents for cost capping and to track dates of last departure to enforce the 60‑day limit.
• Ensure wording in policy documents unambiguously reflects these limits and that claims assessors have the processes required to apply the Australian cost ceiling.

6. Data, recordkeeping and audit trails

• Keep contemporaneous decision records that show what matters were considered and why. Given that rule 9 covers matters “in making a decision, have regard to or fail to have regard to any matter” (9(3)), evidence of decision rationale is essential.
• Maintain a register of decisions relating to overseas students and specified temporary visa holders, including underwriting files, correspondence and the legal basis for decision points.

7. Training and governance

• Train frontline staff, underwriters and claims assessors on prohibited decision factors and on the agency arrangement checklist. Include the need to consult Commonwealth agreements where relevant.
• Update internal compliance manuals and breach reporting frameworks to include the new Rules and the specific obligations under rule 9.
• Add the Rules to the compliance calendar for periodic review and include them in internal regulatory impact assessments.

8. Systems and actuarial adjustments for risk equalisation jurisdictions (rule 8)

• Update actuarial models, reporting templates and risk equalisation calculations to reflect the jurisdiction list in rule 8(1). Map the listed areas to the insurer’s policyholder data to ensure statutory reporting and risk equalisation entries align with the instrument’s groupings.

9. Contract and product‑level gap analysis (Schedule 1)

• Because Schedule 1 repeals the 2015 Rules in full, conduct a gap analysis comparing any legacy contractual terms or administrative practices that referred to the 2015 Rules with the new 2025 Rules. Identify where amendments to product terms, customer communications or provider contracts are required and implement changes by the commencement date (the day after registration, rule 2).

10. Legal and regulatory liaison

• For ambiguous cases (for example, whether a particular overseas treatment qualifies as “routine” or whether a particular characteristic is a permitted basis for differential treatment under a Commonwealth agreement), seek a legal opinion and consider contacting the regulator or the Department for clarification.
• Keep copies of the 2018 Rules and any Commonwealth written agreements on file and ensure legal counsel reviews their interaction with the 2025 Rules.

11. Document retention and potential disputes

• Preserve documentation of pre‑commencement practices for a reasonable period to address any enquiries about transitional conduct, given the full repeal of the 2015 Rules and absence of transitional clauses.

By following these steps and documenting changes, insurers and advisers can align operational practice with the Rules’ specifications. The critical compliance focus areas are the narrow technical tests for overseas treatment (rule 6), the written and liability allocation requirements for agency arrangements (rule 7), the broad prohibition on improper discrimination for certain insured groups (rule 9), and the mapping of jurisdictions for risk equalisation (rule 8).